Table 5.
SCZ PRS and Health and Immune Function.
| Phenotypes | Study Reference | N | Association and Effect size* |
|---|---|---|---|
| Self-reported Health | (Harris et al., 2016) | 111, 749 | Reduced health: B=−0.028 |
| Self-reported Tiredness | (Deary et al., 2017) | 108,976 | Increased tiredness: B=0.028 |
| Amyotrophic Lateral Sclerosis | (McLaughlin et al., 2017)* | 12, 577 patients, 23, 475 CON | ALS have higher PRS: 0.0012 |
| Type 2 Diabetes | (Padmanabhan et al., 2016) | EA: 218 CON, 384 SCZ, SCZA, Psy BIP Probands AA: 104 CON, 257 SCZ, SCZA, Psy BIP Probands |
NS: positive association among probands and relatives, OR up to 1.41: 0.20. |
| Infection and infection-related SCZ | (Benros et al., 2016) | 1,692 SCZ, 1,724 CON | NS: infection or evidence or PRS x infection |
| Psoriasis | (Yin et al., 2016)* | Han Chinese: 1139 psoriasis cases, 1132 controls | AUC = 0.54 [0.51 – 0.58]: 0.0050 |
| Migraine | (Van der Auwera et al., 2016)* | 3, 973 | OR = 0.78 (based on 108 loci): 0.0047 |
Studies only include those using summary statistics from (Schizophrenia Working Group of the Psychiatric Genomics, 2014). Unless otherwise noted, effect size is represented as Nagelkerke’s Pseudo R2 (multiply by 100 to obtain %R2); r = correlation, OR = Odds-ration, B = beta coefficient, AUC = Area Under the Curve. EA = European ancestry. AA = African ancestry. NS= non significant. When pearson’s r, OR, or d were reported, we estimated r2.
*
indicates study with % of variance explained included in Figure 2.